Brief: Tracon Pharmaceuticals Announces Dosing Of 36th Patient In Envasarc Pivotal Trial Triggering Initial IDMC Efficacy Review Expected In Fourth Quarter
26/07/2022 13:19
July 26 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS ANNOUNCES DOSING OF 36TH PATIENT IN
ENVASARC PIVOTAL TRIAL TRIGGERING INITIAL IDMC EFFICACY REVIEW
EXPECTED IN THE FOURTH QUARTER
* TRACON PHARMACEUTICALS INC - INTERIM ANALYSIS IS EXPECTED
TO
OCCUR IN Q4 OF THIS YEAR
* TRACON PHARMACEUTICALS INC - SECOND IDMC INTERIM EFFICACY
ANALYSIS IS EXPECTED IN 2023 FOLLOWING ENROLLMENT OF 92(ND)
PATIENT
Source text for Eikon: ID:nGNX1CjLdl
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants